Ipilimumab

An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.

Also Known As:

Anti-CTLA-4 MAb Ipilimumab; MDX 010; MDX-010; MDX-CTLA-4; MDX010; Yervoy; Anti CTLA 4 MAb Ipilimumab; Ipilimumab, Anti-CTLA-4 MAb; MDX CTLA 4

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ipilimumab: 3324
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ipilimumab: 3324
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        Humanized Monoclonal Antibodies: 217
        Ipilimumab: 3324

Joseph E Muenster Selected Research

Joseph E Muenster Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure